MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • 2016 International Congress

    Outpatient management of Parkinson’s disease: A review of medication changes made to address both motor and non-motor symptoms

    B. Magennis, E.A. Donlon, E.M. Fallon, T. Lynch (Dublin, Ireland)

    Objective: To identify reasons for medication changes at outpatient movement disorder clinics and determine outcome of these changes at next clinic visit. Background: Parkinson's disease…
  • 2016 International Congress

    Patient-centered educational intervention using hand-held electronic devices

    N. Hellmers, A. Hanineva, J.C. Stribling, J. Carter, C. Henchliffe (New York, NY, USA)

    Objective: To examine feasibility, usability and initial efficacy of an e-learning intervention, using an interactive tablet-based slideshow with audio/video and quizzes. Background: Mobile tablet and…
  • 2016 International Congress

    The novel COMT-inhibitor ODM-104 and optimized carbidopa in combination with modified release levodopa reduce levodopa fluctuation and increase minimum concentrations in healthy subjects, when compared to the standard carbidopa/levodopa/entacapone combination

    J. Ellmen, J. Tuunainen, A. Holopainen, T. Sarapohja, M. Scheinin (Turku, Finland)

    Objective: To evaluate the plasma pharmacokinetics (PK) of orally administered modified release (MR) levodopa in combination with the aromatic L-amino acid decarboxylase inhibitor carbidopa and…
  • 2016 International Congress

    Characteristics of patients initiating droxidopa for the treatment of neurogenic orthostatic hypotension (nOH)

    C. Francois, K. McLeod, A. Duhig, A. Ogbonnaya, A. Quillen, J. Cannon, B. Padilla, C.A. Shibao, I. Biaggioni (Deerfield, IL, USA)

    Objective: To understand the characteristics of patients initiating droxidopa therapy for the treatment of neurogenic orthostatic hypotension (nOH). Background: nOH is defined as a fall…
  • 2016 International Congress

    Efficacy and feasibility study of the Medido eletronic medication dispenser in Parkinson’s disease: A multicentre randomized controlled trial

    K. Hannink, L. ter Brake, A. Wertenbroek, K. Movig, J. van der Palen, L. Dorresteijn (Enschede, Netherlands)

    Objective: The aim of this randomized controlled study was to assess the effect of the electronic medication dispenser, Medido, on physical limitations in PD. Background:…
  • 2016 International Congress

    The effect of a structured medication review on quality of life in patients with Parkinson’s disease. An interim analysis

    A. Verbeek, N. Oonk, E. Munster, K. Movig, K. ter Huurne, H. Nijmeijer, J. van der Palen, L. Dorresteijn (Eerbeek, Netherlands)

    Objective: To investigate whether a structured medication review executed by a community pharmacist improves medication adherence and influences quality of life in patients with Parkinson's…
  • 2016 International Congress

    Effect of pharmacist-led interventions on motor symptoms and quality of life in Parkinson’s patients: A pilot study

    C. Stuijt, T.V. Laar (Groningen, Netherlands)

    Objective: Improvement of on-off symptoms in ambulatory patients with Parkinson's disease (PD) by introduction of a multi-faceted medication optimization program. This consisted of a patient…
  • 2016 International Congress

    Roles of combined functional catechol-o-methyltransferase genotypes in Chinese Parkinson’s disease: A cross-sectional survey

    Y. Qian, X. Yang, S. Xu, J. Liu, Q. Xiao (Shanghai, People's Republic of China)

    Objective: To investigate the association of the most common functional catechol-O-methyltransferase (COMT) gene haplotypes with risk to develop of Parkinson's disease (PD) and the association…
  • 2016 International Congress

    Safety and efficacy of pardoprunox for patients with Parkinson’s disease: A meta-analysis

    N. Elsagheer, H. Ahmed, A. Attia, K. Awad, E. Ezzat, M. Abd Elaleem Aziz, A. Negida (Beni Suef, Egypt)

    Objective: The aim of this meta-analysis is to synthesize evidence from published randomized controlled trials (RCTs) about the safety and efficacy of Pardoprunox for Patients…
  • 2016 International Congress

    The kinase Fyn mediates levodopa induced dyskinesias in Parkinson´s disease

    J.E. Ferrario, S. Sanz-Blasco, M. Bordone, A. Damianich, A. Bernardi, G. Gomez, I. Taravini, E. Avale, O. Gershanik (Buenos Aires, Argentina)

    Objective: To pharmacologically manipulate the kinase Fyn as a novel target to control levodopa induced dyskinesias. Background: The management of levodopa induced dyskinesias (LID) in…
  • « Previous Page
  • 1
  • …
  • 29
  • 30
  • 31
  • 32
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An atypical and interesting feature of Parkinson´s disease
  • #25136 (not found)
  • Unusual prolonged survival in multiple system atrophy: A case report
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley